SecBot SecBot
SECBOTREPLAY Home › Report › TARA

TARA · Protara Therapeutics reported strong interim clinical data for TARA-002…

Protara Therapeutics · PRESS-RELEASE filed Mar 10, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 10, 2026 at 08:00 ET

Protara Therapeutics reported strong interim clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC), showing a 68% complete response rate at six months in BCG-Unresponsive patients, alongside Breakthrough Therapy and Fast Track designations for lymphatic malformations. The company raised $86.3 million in a public offering, extending its cash runway into 2028, despite increased R&D and G&A expenses leading to a wider net loss. No revenue was generated as the company remains pre-commercial.

  • TARA-002 demonstrated 68.2% complete response rate at six months in BCG-Unresponsive NMIBC patients (22 evaluable patients)
  • Breakthrough Therapy and Fast Track designations received for TARA-002 in lymphatic malformations (LMs)
  • Completed $86.3 million public offering, bringing cash, cash equivalents, and investments to $197.9 million as of December 31, 2025
  • Cash runway now extends into 2028, funding key milestones including ADVANCED-2/3 and THRIVE-3 trials

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access